Acrobiosystems Co

Acrobiosystems Co P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 27.68. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 116.23 — a change of -76.19% (lower).

P/CF

27.68

YoY

-76.19%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Acrobiosystems Co is 2025 27.68 . P/CF (Price-to-Cash-Flow Ratio) of Acrobiosystems Co was 2024 116.23 . It decreases by -76.19% lower compared to the previous year.

The Acrobiosystems Co P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
1,479.01 CNY
Jan 1, 2019
482.53 CNY
Jan 1, 2020
102.03 CNY
Jan 1, 2021
71.34 CNY
Jan 1, 2022
48.69 CNY
Jan 1, 2023
88.54 CNY
Jan 1, 2024
116.23 CNY
Jan 1, 2025
27.68 CNY
The Acrobiosystems Co P/CF history
YEARP/CFYoY
27.68-76.19%
116.23+31.27%
88.54+81.83%
48.69-31.74%
71.34-30.08%
102.03-78.86%
482.53-67.37%
1,479.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

P/CF (Price-to-Cash-Flow Ratio) of Acrobiosystems Co is 27.68 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Acrobiosystems Co changed from 116.23 to 27.68, representing a -76.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co